Iclusig
Total Payments
$3.6M
Transactions
883
Doctors
680
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $3.6M | 883 | 680 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.8M | 7 | 50.7% |
| Unspecified | $1.6M | 51 | 43.5% |
| Grant | $107,500 | 2 | 3.0% |
| Consulting Fee | $51,800 | 13 | 1.4% |
| Space rental or facility fees (teaching hospital only) | $37,075 | 13 | 1.0% |
| Food and Beverage | $12,886 | 788 | 0.4% |
| Travel and Lodging | $3,248 | 9 | 0.1% |
Payments by Type
General
$2.0M
832 transactions
Research
$1.6M
51 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| OPTIC | ARIAD Pharmaceuticals, Inc. | $1.3M | 0 |
| IST - 022 | ARIAD Pharmaceuticals, Inc. | $84,096 | 0 |
| IST - Hyper-CVAD and Ponatinib in Ph-Positive andor BCR-ABL Positive Acute Lymphoblastic Leukemia ALL | ARIAD Pharmaceuticals, Inc. | $52,624 | 0 |
| Pre-Clinical Cardiovascular effects of TKI's | ARIAD Pharmaceuticals, Inc. | $48,533 | 0 |
| PACE | ARIAD Pharmaceuticals, Inc. | $21,645 | 0 |
| AP24534 Pre-Clinical Mayo - Biliary Tract Cancers | ARIAD Pharmaceuticals, Inc. | $16,558 | 0 |
| Phase I Ponatinib | ARIAD Pharmaceuticals, Inc. | $9,772 | 0 |
| GIST | ARIAD Pharmaceuticals, Inc. | $250.00 | 0 |
Top Doctors Receiving Payments for Iclusig
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Immunopathology | New York, NY | $1.8M | 3 |
| Unknown | — | Tampa, FL | $1.8M | 73 |
| , MD, PHD | Cardiovascular Disease | Boston, MA | $27,075 | 3 |
| , M.D | Hematology | Hackensack, NJ | $6,481 | 8 |
| , M.D | Hematology & Oncology | Houston, TX | $6,292 | 4 |
| , MD | Medical Oncology | Aurora, CO | $3,900 | 2 |
| , MD | Medical Oncology | Monrovia, CA | $3,375 | 2 |
| , M.D | Hematology & Oncology | Sacramento, CA | $2,696 | 3 |
| , MD | Cardiovascular Disease | Boston, MA | $2,500 | 1 |
| , MD, PHD | Internal Medicine | Ann Arbor, MI | $2,464 | 4 |
| Stanley Walker | — | Baltimore, MD | $85.92 | 3 |
| , MD | Hematology & Oncology | Shreveport, LA | $66.69 | 1 |
| , M.D | Medical Oncology | Chevy Chase, MD | $61.34 | 2 |
| Frederick Barr | — | Chevy Chase, MD | $61.34 | 2 |
| , M.D | Hematology & Oncology | Oakland, CA | $61.07 | 3 |
| , M.D | Hematology & Oncology | Winston Salem, NC | $52.96 | 3 |
| , MD LLC | Internal Medicine | Lakewood, NJ | $49.43 | 3 |
| William Stanton | — | San Diego, CA | $47.71 | 2 |
| , M.D | Internal Medicine | San Diego, CA | $47.71 | 2 |
| , M.D | Hematology & Oncology | La Jolla, CA | $46.39 | 2 |
| , MD | Hematology & Oncology | Van Nuys, CA | $45.23 | 2 |
| , MD | Hematology & Oncology | Media, PA | $45.10 | 3 |
| , MD | Hematology & Oncology | San Diego, CA | $44.60 | 2 |
| , D.O | Hematology & Oncology | Escondido, CA | $43.90 | 2 |
| , M.D | Hematology & Oncology | Anaheim, CA | $43.41 | 3 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.6M
- Total Doctors 680
- Transactions 883
About Iclusig
Iclusig is a drug associated with $3.6M in payments to 680 healthcare providers, recorded across 883 transactions in the CMS Open Payments database. The primary manufacturer is ARIAD Pharmaceuticals, Inc..
Payment data is available from 2017 to 2017. In 2017, $3.6M was paid across 883 transactions to 680 doctors.
The most common payment nature for Iclusig is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.8M, 50.7% of total).
Iclusig is associated with 8 research studies, including "OPTIC" ($1.3M).